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bstract
After diagnosis of non-functioning pituitary adenoma and impact assessment (pituitary deficiency, visual field disorder), the question of manage-
ent arises between surgery and surveillance. This part of the Consensus document aims to clarify the principal situations encountered in clinical
ractice (visual disorder, pituitary deficiency, asymptomatic adenoma, etc.), so as to determine which ones indicate surgery and which ones simple
urveillance. Particular contexts are also dealt with (elderly patients, young women hoping for pregnancy, etc). The principal surgical techniques
microscopy, endoscopy, etc.) are also considered. Finally, in case of surgery, the principal pathologic criteria are specified (immunolabeling,
roliferation markers, etc.).
 2015 Elsevier Masson SAS. All rights reserved.
eywords: Pituitary adenoma; Pituitary deficiency; Visual field defect; Elderly subject; Pregnancy; Ki67; p53; Silent pituitary adenoma
ésumé
Après l’étape de diagnostic positif d’adénome hypophysaire non sécrétant, et l’étape d’évaluation du retentissement (déficit hypophysaire,
ltérations campimétriques), se pose la question de la prise en charge : chirurgie ou surveillance. Cette partie du consensus a pour objectif de
éterminer quelles situations rencontrées en pratique clinique (altération campimétrique, déficit hypophysaire, absence de retentissement. .  .)
ustifient d’une prise en charge chirurgicale ou d’une simple surveillance. Les cas particuliers tels que le sujet âgé, la femme jeune avec désir de
rossesse.  .  .  seront également évoqués. Enfin seront précisés les principales techniques chirurgicales, et les renseignements indispensables que
evra comporter le compte-rendu anatomo-pathologique. 2015 Elsevier Masson SAS. Tous droits réservés.ots clés : Adénome hypophysaire ; Déficit hypophysaire ; Anomalie du champ vis
DOIs of original articles: http://dx.doi.org/10.1016/j.ando.2015.04.004, http://dx.
ttp://dx.doi.org/10.1016/j.ando.2015.04.002, http://dx.doi.org/10.1016/j.ando.2015.0
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.  Introduction
After diagnosis of non-functioning pituitary adenoma and
mpact assessment (pituitary deficiency, visual field disorder),
he question of management arises, between surgery and surveil-
ance. This part of the Consensus document aims to clarify the
rincipal situations encountered in clinical practice, and to spec-
fy the criteria rendering surgery necessary, possible, or else,
ebatable with respect to simple surveillance. The principal sur-
ical techniques are specified. Finally, the principle pathologic
riteria to be determined on the operative specimen in case of
urgery are defined to adapt postoperative treatment in case of
emnant.
.  Indications  for  surgery
.1.  Symptomatic  adenoma
.1.1.  Visual  disorders
Improved vision is reported in some 80–90% of cases (includ-
ng both partial and total recovery) [1,2]. Recovery may be
rogressive, over a period of up to 1 year after surgery. Some
tudies highlighted a correlation between percentage recovery
nd duration and severity of campimetric disorder (acuity < 1/10
r optic atrophy being of poor prognosis) [3,4]. In case of demon-
trable visual disorder, surgery should therefore not be delayed;
he urgency depends on the severity of visual impact. There are
o clear data for a threshold time beyond which visual recov-
ry after chiasma decompression is no longer possible. Visual
isorders are an indication for surgery, even though complete
ecovery cannot be guaranteed.
.1.2.  Pituitary  deﬁciency
The risk of onset of further pituitary deficiency associated
ith macroadenoma is estimated at 12% per year. Arafah et al.
orrelated preoperative deficiency, headaches and hyperpro-
actinemia to the potential for postoperative recovery: when all
he criteria were met, postoperative recovery of deficiency and
mprovement in headaches were more frequent [5,6], correlating
ith intrasellar pressure. Surgery provided recovery of normal
nterior pituitary function in about 30% of cases, at a mean of 1-
ear follow-up [7]; the rate was higher for earlier management.
ome teams indeed recommend surgery at the asymptomatic
tage of macroadenoma [7]. The risk of postoperative deteri-
ration in pituitary function is about 10% [3]. Postoperative
ecovery being uncertain, pituitary deficiency is thus probably
ot the main factor indicating surgery.
.1.3. Headaches
The involvement of pituitary adenoma in headaches can only
e established after ruling out all other possible causes (possibly
fter referral to a neurologist) and determining time of onset in
elation to the natural history of the adenoma.Headaches are classically due to distension of the dural
nvelopes [8]. Retro-orbital or vertex locations suggest pituitary
tiology. If headaches do indeed implicate adenoma, surgery
eems to be effective in relieving symptoms [3,9,10]. Disabling
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eadache implicating adenoma thus seems to be an indication for
on-emergency surgery, warning the patient that no direct causal
elation can be proven and thus results cannot be guaranteed.
.2.  Asymptomatic  adenoma
Surgical indications are founded on several factors:
 patient age. Non-emergency surgery may be considered in
young patients without awaiting progression, given the low
risk of postoperative visual impairment, the almost inevitable
progression of adenoma over the long term, and the risk
of definitive postoperative visual impairment if surgery is
delayed awaiting onset of a campimetric visual-field effect;
 the natural history of non-functioning adenoma (possible
spontaneous increase or decrease in tumor volume). Losa et al.
recently stressed that the risk of postoperative recurrence was
lower with early surgery [11];
 the risk of onset of campimetric impairment, correlated with
the rate of tumor growth and proximity to the optic pathways;
 the risk of onset of pituitary deficiency (12% per year in
macroadenoma);
 the risk of apoplexy (estimated at 1% per year in the absence
of extra risk factors: see corresponding Consensus article);
 risks inherent to trans-sphenoidal surgery: mortality is less
than 1%; the risk of severe adverse events (osteomeningeal
breach, meningitis, visual deterioration) is less than 5%; the
risk of diabetes insipidus may reach 10%.
Progression is slow in microadenoma and surgery is not indi-
ated. The natural progression of macroadenoma may indicate
on-emergency surgery, depending on evolutive status, proxim-
ty to the optic pathways, and the patient’s age.
.3.  Special  cases
.3.1.  Elderly  patients
Most studies set a threshold of 65 years for elderliness: phys-
ological age would seem more relevant. There are, however, no
ata on complications or efficacy in patients aged over 75 years
t diagnosis. Most studies combined secreting and non-secreting
denomas, making it difficult to know whether the complications
eported relate exclusively to non-secreting adenoma.
Non-functioning adenoma accounts for 60–80% of adenomas
n the “elderly”, with incidence around 7% [12–14]. Character-
stics seem to be identical to those found in “young” subjects,
articularly as regards signs at diagnosis: the main presenting
ymptom is visual impairment, in 50–70% of cases [13]. Most
atients present with macroadenoma of 2–4 cm on the long axis
12].
Therapeutic decision-making needs to take account of visual
mpact, proximity to the chiasm, and comorbidity: 80% of
atients have at least 1 comorbidity [12]. Anesthesia risk
ssessment is crucial, 10% of patients having ASA risk scores
ontraindicating surgery [15]. One study suggested that non-
ecreting adenoma growth is slower in elderly subjects [16].
he risk of apoplexy, in the absence of extra risk factors (notably,
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ntiplatelet and anticoagulant treatments) is identical to that for
he pituitary adenoma population as a whole [17].
Mortality is no higher than in the general population if
nesthesia risk is well assessed (< 1% of mortality) [13]. The
ates of visual recovery and recovery of pituitary deficiency
re comparable to that of young subjects: 75% and 30%,
espectively. Studies have reported higher rates of mortal-
ty and complications associated with craniotomy than with
rans-sphenoidal surgery, and the latter approach should be the
eference: the risk of severe complications (breach, meningitis)
s identical. Hospital stay is longer (up to 20 days, depending on
he report) [12], which may be due to a slightly higher rate of
ostoperative hydro-electrolytic disorder (10% versus 6% in the
eneral population) [14], although some studies fail to confirm
t and find no age-related difference [13,15]. There is a risk of
isual deterioration in 1–10% of cases.
Indications in 65–75 year-olds are the same as in young sub-
ects, if comorbidity, anesthesia risk and patient impact are well
ssessed. In case of surgery, the approach should preferably be
rans-sphenoidal, so as not to increase the risk of complications.
n the absence of visual impact, simple annual MRI surveillance
s sufficient. The lack of data for over 75 year-olds is to be borne
n mind.
.3.2.  Young  women  with  or  without  pituitary  deﬁciency
Non-functioning adenoma is rare in young women, and pub-
ished data are sparse [18].
In case of visual field impairment, surgery is mandatory and
hould be undertaken quickly [19].
In the absence of visual field impairment in a patient with
acroadenoma and hoping for pregnancy, the decision to oper-
te may be based on gonadotroph deficiency: surgery provides
ituitary recovery in about 30% of cases (depending on pro-
ression), while deficiency is found at diagnosis in more than
0% of cases [8]. Gonadotroph deficiency may also be due to
isconnection hyperprolactinemia, which usually resolves with
urgery [19].
When pregnancy is sought and there is no gonadotroph defi-
iency, the risk of tumor growth during pregnancy needs to be
aken into account, although it is theoretically low, pregnancy
eing principally characterized by lactotroph cell hyperplasia;
owever, in association with macroadenoma, this may cause
hiasmal compression, as reported in some cases [18,20]. The
ecision to operate should therefore be based on adenoma
ize and proximity to the optic pathways: maximum pituitary
land height can increase by 12 mm during pregnancy [19].
n abstention from surgery, clinical surveillance should be at
east 3-monthly, with visual field test and MRI without con-
rast enhancement in case of tumoral syndrome onset during
regnancy. The risk of apoplexy is slightly increased during
regnancy [17].
If there is no pregnancy project in the medium term and no
ituitary deficiency, the decision to operate is guided by the
atural history of non-functioning adenoma: specifically, size
nd proximity to the optic pathways. Surgery is not urgent. It
s not indicated in microadenoma, and may be considered on a
on-emergency basis in macroadenoma remote from the optic
e
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athways. Dekkers et al. reported that the risk of increase in
acroadenoma size probably correlated with length of follow-
p, with increase in 50% of cases for ≥  5-years follow-up.
pontaneous reduction in size is rarer, reported in 11% of cases
3]. Two attitudes are possible: MRI surveillance with surgery
n case of progression, or first-line surgery [21]. Progression
rom micro- to macro-adenoma is rare; in microadenoma in a
oung female patient, emergency surgery is therefore not indi-
ated except in case of progression on MRI at 6 months to 1 year
3].
For young female patients, surgery should respond quickly
o any impairment of visual field. Gonadotroph deficiency is
lso an indication for surgery, although postoperative recov-
ry is unsure. Pregnancy is not theoretically a risk factor for
ncreasing adenoma volume, but there is a risk of campimet-
ic impairment if the adenoma is close to the optic pathways. In
hat case, surgery should be considered; if it is not implemented,
lose clinical surveillance and visual field testing should accom-
any the pregnancy. If no pregnancy is planned and the adenoma
hows no impact, MRI surveillance should be proposed, or else
urgical intervention without awaiting progression.
.3.3.  Antiplatelets  and  anticoagulants
Anticoagulants: in the general population, the incidence of
emorrhage associated with anti-vitamin K (AVK) is estimated
t 7% per year, and mortality at 1% [22]. AVK is associated with
 to 10-fold elevation of spontaneous intracerebral bleeding.
ithdrawal of AVK (in favor of heparin) is recommended 5 days
head of surgery, to obtain normal INR (international normalized
atio), with reintroduction in the following 7 to 14 days.
Antiplatelets: the risk of intracranial hemorrhage is low. A
tudy of meningioma surgery, however, associated antiplatelets
ith postoperative hematoma [23]. Preoperative withdrawal, on
he other hand, is associated with increased morbidity and mor-
ality, especially in patients with active stents; withdrawal thus
equires the opinion of a cardiologist, 5 days ahead of surgery
or aspirin and ideally 10 days ahead of surgery for clopidogrel.
Published data are scarce. A French study of 546 patients
ndergoing adenoma surgery while under long-course anti-
oagulants or antiplatelets reported a 6-folds rise in risk
f postoperative hemorrhagic complications (epistaxis or
ematoma of the operative cavity in 6% of cases, compared to
.9% in the group without anticoagulants or antiplatelets) [24].
There are presently no guidelines on withdrawal of antico-
gulants and antiplatelets. Continuation doubtless increases the
isk of postoperative hematoma. The decision should be made in
oordination with the neurosurgeon, cardiologist and anesthesi-
logist.
Long-course anticoagulants or antiplatelets also increase the
isk of pituitary apoplexy, which should be taken into account
n deciding between surveillance and surgery.
.  Surgical  optionsSurgery for pituitary adenoma is no exception to the mod-
rnization of techniques and operating theater environment:
iagnostic MRI, endoscopy, neuronavigation, intra-operative
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maging. It is to be borne in mind that non-functioning adenoma
s rarely aggressive, and a systematically maximalist attitude is
o be eschewed. In certain cases, however, 2-step or extended
urgery, possibly using an endocranial approach, may be neces-
ary due to the complexity and/or aggressiveness of the tumor.
.1.  Endoscopy  versus  microsurgery
In non-functioning pituitary adenoma, which is almost
lways macroadenoma, surgery aims at optimal resection with
inimal morbidity. Complete resection is certainly desirable,
reventing recurrence or progression. At each stage of manage-
ent, potential iatrogenic morbidity is to be weighed against
he frequently benign nature of these tumors, and this balance
s to be struck on a case-by-case basis. The quality of present-
ay imaging enables very reliable long-term follow-up, which
ay allow partial or subtotal resection, at lower cost, rather than
omplete resection with its risk of complications.
Since the 1960s and the work of Guiot and Hardy, the gold
tandard for pituitary surgery has involved a trans-sphenoidal
pproach under operative microscopy and intra-operative
adiological guidance [25,26]. The approach was initially
escribed as sublabial rhinoseptal trans-sphenoidal: i.e., under
he upper lip, along the nasal septum and across the sphenoidal
eptum. The surgeon made an incision in the superior gingival
roove, resected or dislocated the nasal septum, removed the
phenoidal rostrum and opened the sphenoidal sinus to insert
 speculum. Access to the adenoma was via the sella turcica
oor, by fragmentation-aspiration resection. To simplify nasal
ostoperative course and increase comfort, a pure endonasal
pproach was introduced by Griffith and Veerapenen in 1987
27]. In this variant of the sublabial approach, the surgeon
ccessed the sphenoidal sinus directly via one of the nasal
avities. Once the speculum was in position and the sphenoidal
inus open, surgery proceeded as on a sublabial approach. A
ecent modification by Kerr and Oldfield in 2008 did not greatly
iffer from the reference technique developed by Guiot and
ardy [28]. Since then, no randomized studies have demon-
trated superiority between the initial technique and any of its
ariants, or indeed superiority for microscopy, although it is
ncontestably essential in neurosurgery and pituitary pathology.
Techniques, however, have shifted in favor of endoscopy,
ue to the frequent problem of postoperative residua (ranging
rom 70% to 10% in the main series) and the discomfort of sev-
ral days’ nasal packing and frequent upper gum hypoesthesia,
ombined with progress in nasal endoscopy in ENT pathology.
In the early 1990s, following an initial publication by
ankowski et al. in 1992 and North American and Italian stud-
es, endoscopy began to compete with microscopy, which it
eplaced in certain teams [29–32]. Postoperative comfort is
etter. Complication rates, once the initial learning curve has
assed, are comparable between microsurgery and endoscopy
33–36]. There have been no prospective randomized series to
emonstrate superiority one way or the other, but the experi-
nce of expert pituitary surgery teams testifies to better control
f lateral and superior extension under endoscopy and a review
f endoscopically managed non-functioning pituitary adenomas
n
e
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ound a higher mean rate of macroscopically total resection
34,37]. Catapano et al.’s cadaver studies and Mattozzo et al.’s
linical studies of patients undergoing surgical revision for
esiduum found wider sella turcica opening with endoscopy
ompared to microscopy and, in the latter study, that primary
pening had been too narrow [38,39]. Finally, a recent meta-
nalysis by Ammirati et al. found no benefit of endoscopy over
icroscopy in terms of resection quality, but rather a higher rate
f vascular complications; the meta-analysis, however, covered
ll endoscopy series, including early learning curves, whereas
he microscopy series reported results from teams beyond the
earning stage [40].
At all events, microscopy surgery is progressively being
eplaced by endoscopy; more than the instrument, however, it
s the surgeon’s experience that counts. Objectives and indica-
ions are the same, in either case. Placing endonasal pituitary
urgery in the context of other surgical specialties (urology,
NT, abdominal and gynecological laparoscopic surgery) treat-
ng hollow organs or using cavities such as the nasal fossae, it is
ore than likely that, within two decades from now, endoscopy
ill have entirely supplanted microscopy in pituitary adenoma
urgery.
Complications are few in pituitary surgery (essentially, ENT,
ndocrine or ophthalmologic morbidity, osteomeningeal breach,
eningitis and vascular wounds) and directly correlated with the
urgeon’s experience, arguing for hyperspecialization in pitu-
tary neurosurgery [41,42].
.2.  Two-step  surgery,  extended  and  endocranial
pproaches
Endoscopy also enables extended approaches, with access
o the intradural compartment, by removing the tuberculum
ellae, chiasmatic groove and posterior part of the jugum sphe-
oidale (transtubercular approach). This may be useful in case
f suprasellar extension that refuses to descend after intrasellar
ebulking. In this case, 2-step surgery may also be considered:
erebral pulsation will, in many cases, cause the suprasel-
ar expansion to migrate into the sella turcica, rendering it
ccessible on a repeated classical trans-sphenoidal approach.
wo-step surgery is less aggressive than an extended approach,
lthough requiring a second general anesthesia and second
ospital admission. The intra-operative decision criteria are sub-
ective. Two-step surgery is a useful option if the suprasellar
esiduum is not too large and intra-operative hemostasis can
e achieved. Otherwise, there is a severe risk of hemorrhagic
poplexy of the suprasellar fragment, and an extended 1-step
rocedure is preferable. The decision is made intra-operatively.
ituations encountered can be very variable; attitudes vary from
eam to team, and it is difficult to draw up any rule. Likewise for
ndocranial approaches: in some rare cases of sometimes giant
denoma with anterior, retroclival or lateral extension toward the
ylvian fissure, or “mushrooming” in or toward the central gray
uclei, either an isolated endocranial approach or a combined
ndocranial and transsphenoidal approach, in a single step or at
 few days’ or weeks’ interval, may be used [43–45]. There are
o rules as to the sequence and timing of a combined approach.
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ndications are rare and mainly concern expert centers; the deci-
ion depends essentially on tumor extension, but also on team
xperience and habits.
.3.  Role  and  beneﬁt  of  intra-operative  imaging
Historically, the first method of intra-operative guidance was
adioscopy, providing information exclusively in the sagittal
lane. The method is now obsolete, and moreover exposes all
hose present in the surgery room, as well as the patient, to
onizing radiation.
Neuronavigation based on preoperative CT and/or MRI pro-
ides information in all 3 planes and is the method now used for
ntra-operative guidance in neurosurgery. Resolution is now of
he order of a millimeter [46]. There are no randomized stud-
es demonstrating benefit, but it is applicable in the following
ircumstances:
 training: notably in the early learning curve, to gain familiarity
with the endonasal endoscopic approach;
 teaching: to point out the anatomic details of the various stages
of the approach;
 in case of unusual anatomy or remodeling (sinus concha,
acromegaly);
 when the usual anatomic landmarks are liable to be lost, as in
adenoma that has destroyed or invaded the sphenoidal sinus,
or in surgery for recurrence in which the previous landmarks
have been damaged or removed by primary surgery;
 whenever surgery is “extended” to structures neighboring the
sella turcica.
Intra-operative CT and/or MRI are probably the attitude of the
uture. In a non-dedicated surgery room, however, only a low-
eld low-definition system is feasible. High fields (1.5 Tesla and
bove) are more reliable in assessing intra-operative residua, but
equire specific and very costly equipment, not available in most
enters. The true benefit of intra-operative MRI remains to be
stablished [47]. Publications from centers in which it is used
ave been encouraging [48–51].
.  Anatomopathology
.1.  General  considerations
Clinically and/or biologically non-functioning pituitary ade-
oma cover 3 different histologic types according to the current
athology classifications [52]:
 gonadotroph adenoma (FSH/LH) and the non-
immunoreactive variant known as “null cell adenoma”,
which constitute the great majority [53–55];
 silent corticotroph adenoma (ACTH), also known as “silent
type 1 or 2 adenoma” (reviewed in [56]);
 and silent somatotroph (GH) or mixed GH-PRL adenoma
(GH-PRL ±  TSH), also known as “silent subtype 3” [57–59].
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The first clinical [60] and histological [61] descriptions of
ituitary adenoma with FSH hypersecretion date back to almost
0 years, and the first series (8 cases) of gonadotroph adenoma
ith and without LH/FSH hypersecretion to more than 30 years
55].
In Lyon (France), pathology series of more than 3000
umors studied immunocytochemically since 1986, the rate
f non-functioning adenoma was 35%. With improvements in
he sensitivity and reproducibility of automated immunocyto-
hemistry since 2007, the proportion of non-immunoreactive
denomas has fallen from 15% to 1% and that of gonadotroph
denoma has risen from 22% to 35% (178/502 tumors oper-
ted on in 2007–2012). Silent GH-PRL and ACTH adenoma
ow accounts for 8% of operated adenomas and 18% of non-
unctioning adenomas (40/218), silent ACTH adenoma being
he most frequent form. In clinical and neurosurgical series,
hese 3 types of non-functioning adenoma are often, mistak-
nly, grouped together for analysis, whereas they are in fact very
ifferent histologically and clinically, and probably in terms of
rogression.
.2.  Clinicopathologic  data
.2.1.  Tumor  size  and  invasion
At the present time, pathologic diagnosis of pituitary
denoma and of non-functioning adenoma in particular (cf.
heck-list below) should include imaging data and intra-
perative findings to assess tumor size and invasive/non-invasive
tatus, as histological proof is possible in only 10% of tumors
ound to be invasive on MRI: the intracavernous fragment close
o the internal carotid artery is rarely included in the specimen.
.2.2. Histology,  immunocytochemistry  and  proliferation
Non-functioning adenoma is identifiable on immunohisto-
hemistry, but silent ACTH or GH-PRL adenoma may also be
uspected on histology as their aspect resembles their symp-
omatic clinical variant with acromegaly or Cushing’s disease.
e deal here only with gonadotroph adenoma.
Gonadotroph adenoma shows diffuse or, more often, a
ord arrangement, with well-developed vascularization; in rare
ases, it may be hemorrhagic or necrotic. The cells are
ell-delineated, oval or polyhedral, without signs of secre-
ion (small nuclei without nucleoli). Immunocytochemistry is
ndispensable, but involves technical problems relating to fixa-
ion and antibody specificity. Gonadotroph hormone detection
s negative with AFA fixation and rare with 4% buffered
ormaldehyde; some antibodies show negative or non-specific
eaction. The fixative, preferably formaldehyde-zinc, and the
ntibody reference (clone) should be specified in the pathology
eport. In immunocytochemistry, all cells are strongly positive
o anti-chromogranin A antibodies. Thus, strongly and dif-
usely expressed chromogranin A in necrotic adenoma suggests
onadotroph adenoma, reaction with anti-pituitary hormone
ntibodies being usually negative. In gonadotroph adenoma, the
ercentage of cells immunoreactive to anti-gonadotroph hor-
one antibodies varies from 100% to a few islands, and is
sually low (20–30%), with immunoreactive cells localized by
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rea (Appendix A). In some tumors, cells are positive for all
 FSH, LH and -sub-unit antibodies, while in others they
re positive only for FSH or, more rarely, LH or   sub-unit.
hen only few cells (< 5%) are immunoreactive, null-cell type
denoma is diagnosed, although it secretes gonadotroph hor-
ones in culture and shows granulation on electron microscopy.
lurihormonal gonadotroph adenoma is rare, except in type-1
ultiple endocrine neoplasia (MEN1) [62]. In case of remnant
nd especially of progression, somatostatin receptor detection
s performed, using new highly specific antibodies to guide
omatostatin analog prescription: 26% of gonadotroph ade-
omas express type-2 somatostatin receptor (SSTR2), SSTR5
eing rare and often focal [63].
To assess the risk of recurrence or progression, it is important
o specify proliferative status by systematically testing the 3
roliferation markers: proliferation index assessed on Ki-67
ntibody, mitotic activity, and p53 expression. Ki-67 expression
as been especially well studied [64,65]. Results concerning
ssociation with invasiveness and recurrence/progression are
ontradictory. However, automated immunocytochemistry
akes detection of these nuclear markers more reproducible,
nd analysis of the literature, including the recent studies by
affrain-Rea et al., [66] and Righi et al., [67], shows that Ki-
7 > 3% predicts recurrence/progression with high specificity
89%) but poor sensitivity (54%). The interest of mitotic activity
nd p53 expression is even more debatable. We suggest noting,
n the pathology report, the number of mitoses per 10 wide
elds with a 40×  magnification lens, with a threshold of n  > 2,
nd P53 expression (positive for > 10 positive nuclei per 10
ide fields at 40×), or as percentages. In some recurrent tumors
r even carcinomas with metastasis, the Ki-67 index may be low
nd the mitosis count high. We therefore recommend testing all
 markers systematically, classifying the tumor as proliferative
nly when at least 2 are above threshold. Following the multi-
isciplinary multicenter HYPOPRONOS study, we recommend
 new classification in 5 grades, the prognostic value of which
as been demonstrated on multivariate analysis (P  < 0.001)
68]. Other molecular markers have also been described for non-
unctioning pituitary adenoma, but their prognostic value with
egard to recurrence and progression remains to be validated.
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ppendix  A.  Pathology  check-list
. MRI
Size: Micro Macro Giant
Invasion: yes nof yes:
Cavernous sinus yes no
Sphenoidal sinus yes no
Intra-operative confirmation yes no
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I.  Histology
.  Fixatives
ormaldehyde-zinc yes no
ouin Hollande yes no
NB:  Other  ﬁxatives  (AFA,  neutral  formaldehyde)  not  recom-
ended  due  to  ICC  problems.
. Histology
Invasion yes no ND
If yes: Location
avernous sinus Sphenoidal sinus Dura-mater Juxta-tumoral pituitary gland
.  ICC
a) Antibodies for typing
- ßFSH, ßLH, SU, Chromogranin A gonadotroph ade-
noma
- PRL–GH silent GH or GH/PRL adenoma
- ACTH silent corticotroph adenoma
) For proliferation
itosis count n = (threshold, n > 2/10 40×  fields)
i-67 index: (threshold ≥ 3%)
53 detection: (+ for > 10 nuclei/10 40×  fields)
To be discussed: type 2 and 5 somatostatin receptors
II.  Molecular  biology
To be discussed: fragment freezing and conservation at
80 ◦C for micro-array, PCR and CGH study.
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